About Lek
Lek is a Healthcare company based in Ljubljana (Slovenia) founded in 1946, and was acquired by Novartis in October 2002. Generic pharmaceuticals are developed and manufactured by Lek. Its website lek.si draws about 31 thousand monthly visits. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified. Its legal entity is Maine Potato Growers, Inc.
Company details
Lek was established in 1946 in Ljubljana, Slovenia, as a developer, producer, and distributor of generic pharmaceuticals. Operations focus on anti-infectives, cardiovascular, and gastrointestinal products. Marketing approvals were secured in the US for bromocriptine, used in Parkinsons treatment, and lisinopril for hypertension management. Acquisition by Novartis occurred in 2002, with integration into the Sandoz generics division following in 2003.
Funding Insights of Lek
- Total Rounds 1
- Last Round Grant — $2.94M
- First Round $2.94M
(Mar 2015)
- Investors Count 1
All 1 funding rounds of Lek with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2015 | $2.94M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Lek
Lek has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Novartis and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Lek
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Lek
3 dated milestones of Lek across 69 years, from founding to its latest funding, stage changes and deals.
- Founded Lek is founded.
- Exit Acquired by Novartis.
- Funding First funding round of $2.9M.
Web traffic of Lek
The website of Lek (lek.si) receives about 30.5K visits a month.
- Monthly visits30.5K
▲ 21.7% vs previous month
Websites whose visitors overlap most with Lek. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
krka.si | krka.si | 100% | #529,591 | – | |
lekarna24ur.com | lekarna24ur.com | 84% | – | ||
| hexal.de | 82% | 45.3K | #717,456 | View details | |
ezdravje.com | ezdravje.com | 82% | #4,222,651 | – | |
vizita.si | vizita.si | 78% | #60,795 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 25 similar websites and full traffic analytics for Lek
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 25 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Lek
Lek was founded in 1946 and raised its 1st funding round 69 years after it was founded.
Lek is headquartered in Ljubljana, Slovenia.
Lek was established in 1946 in Ljubljana, Slovenia, as a developer, producer, and distributor of generic pharmaceuticals. Operations focus on anti-infectives, cardiovascular, and gastrointestinal products. Marketing approvals were secured in the US for bromocriptine, used in Parkinsons treatment, and lisinopril for hypertension management. Acquisition by Novartis occurred in 2002, with integration into the Sandoz generics division following in 2003.
Lek has 2 investors. Key investors include Novartis, and European Union.
Lek operates through Maine Potato Growers, Inc.
Yes. Lek was acquired by Novartis in October 2002.